论文部分内容阅读
为探讨儿童急性白血病时Bcl_2、P53蛋白表达与化疗效果及预后之间的关系 ,用SP免疫组化法对不同组骨髓细胞进行Bcl_2、P53蛋白检测。结果显示 ,Bcl_2、P53蛋白表达率在初治组与难治复发组均显著大于缓解组与对照组 (P<0.05,P<0.001);难治复发组Bcl_2、P53蛋白表达率显著高于初治组(P<0.05) ;Bcl_2蛋白表达率在初治组中ANLL显著高于ALL ,而在难治复发组中无差异。随访20例中 ,Bcl_2、P53蛋白同时阳性者2例 ,6周内均未缓解 ;2种蛋白均阴性者6例 ,缓解率达100 %(P<0.05) ,随访3年均持续完全缓解。提示检测骨髓细胞Bcl_2、P53蛋白表达水平 ,可预测儿童急性白血病化疗效果及预后状态
To investigate the relationship between the expression of Bcl-2, P53 and the chemotherapeutic effect and prognosis in childhood acute leukemia, Bcl-2 and P53 protein were detected by SP immunohistochemistry in different groups of bone marrow cells. The results showed that the expression rates of Bcl-2 and P53 protein in the untreated and refractory relapsed group were significantly higher than those in the remission and control groups (P <0.05, P <0.001) (P <0.05). The expression of Bcl-2 protein in ANC group was significantly higher than that in ALL group, but no difference in the refractory and relapsed group. In the 20 cases followed up, 2 cases with both Bcl-2 and P53 protein positive were not relieved within 6 weeks. 6 cases with both protein negative and 6 cases with complete remission rate were 100% (P <0.05). Prompt detection of Bcl 2, P53 protein expression in bone marrow cells can predict the efficacy and prognosis of children with acute leukemia chemotherapy